NGS Targeted Hotspot Panel (For Illumina® Platforms)

Cat Number: THSP-ILNGS

The NGS Targeted Hotspot Panel is a multiplexed next-generation sequencing assay designed to detect key somatic mutations and copy number variations across 16 clinically relevant cancer genes for comprehensive tumor profiling in research applications.

Covers and detects all clinically relevant hotspot mutations in 17 genes
Includes reagents for target enrichment; library preparation, clean up, sample and library QC
Compatible with Illumina® NextSeq 500, MiniSeq, and MiSeq sequencers
Complimentary data-analysis software for local installation available
40 tests per kit
For research use (RUO) in the U.S
For in vitro diagnostic use (IVD) in the European Union

Category: Pan Cancers Tags: BRAF, C-KIT, EGFR, ERBB2, HRAS, IDH1, IDH2, JAK2, KRAS, MET, NRAS, PDGFRA, PIK3CA, RET, TERT, TP53

The NGS Targeted Hotspot Panel is a next-generation sequencing (NGS) assay designed to detect clinically relevant somatic mutations and copy number variations (CNVs) in solid tumors.

The NGS Targeted Hotspot Panel employs a highly multiplexed, tiled amplicon-based enrichment strategy to ensure efficient and comprehensive coverage of critical hotspots. The assay targets 200 amplicons with an average size of 164 base pairs, optimized for high-performance sequencing. Indexed PCR and adapter ligation prepare libraries for compatibility with Illumina® sequencing platforms.

The kit includes all necessary reagents for target enrichment and library preparation, and is validated for use with DNA derived from a variety of sample types including FFPE tissues, blood, fresh or frozen specimens, and cell lines. EntroGen’s Variant Analysis (EVA) software complements the panel by enabling intuitive reporting of single nucleotide variants (SNVs), small insertions/deletions (indels), and focal gene amplifications.

For laboratories conducting comprehensive tumor profiling, the NGS Targeted Hotspot Panel offers a robust and streamlined solution to support personalized cancer research and precision oncology applications.

The panel targets hotspot regions in 16 cancer-associated genes:

Gene	Disease	Coverage
BRAF	Melanoma, Colorectal, Lung	Exons 11 & 15
EGFR	Lung, Glioma	Exons 3, 7, 12, 15, 18, 19, 20, 21
ERBB2	Breast, Lung	Exons 8, 14, 17, 18, 19, 20, 21, 24, 26
HRAS	Thyroid	Exons 2, 3
C-KIT	GIST, Melanoma	Exons 2, 8, 9, 10, 11, 13, 14, 15, 17, 18
IDH1	Glioma, AML	Exon 2
IDH2	Glioma, AML	Exon 4
JAK2	Bone Marrow Disorders	Exon 12, 14
KRAS	Colorectal, Lung	Exons 2, 3, 4
MET	Lung	Exons 2, 11, 14, 16, 18, 19, 20
NRAS	Colorectal, Melanoma	Exons 2, 3, 4
PDGFRA	GIST	Exons 12, 14, 15, 18
PIK3CA	Colorectal, Breast, Ovarian	Exons 1, 4, 6, 7, 9, 13,18, 20
RET	Thyroid	Exons 10, 11, 13, 15, 16
TERT	CNS, Bladder, Thyroid, Skin	Promoter
TP53	Breast, Ovarian, Skin, Lung, Colorectal	Entire Exome
PTEN*	Endometrial, Glioma, Prostate, Breast, Colon	Exons 1-9

*Available upon request

For More Information

The NGS Targeted Hotspot Panel provides a streamlined and robust next-generation sequencing (NGS) workflow for the detection of somatic mutations and copy number variations in cancer-associated genes. The assay is compatible with DNA extracted from blood, fresh frozen tissues, cell lines, and high-quality FFPE samples, and is optimized for use on Illumina® sequencing platforms. Genomic DNA from FFPE tissues can be extracted using EntroGen pureNA® Genomic DNA Isolation Kit.

This kit includes reagents required for target enrichment, library preparation, and indexing to ensure accurate and efficient sequencing. The workflow involves DNA quantification, highly multiplexed PCR-based target enrichment, and adaptor ligation, followed by purification and generation of NGS-ready libraries.

Reagents and columns for DNA isolation are not included. To ensure optimal assay performance, DNA input should be quantified using a qPCR-based method prior to library preparation.

The following suplimentary products are available, but not supplied: